Active domestication of the Korean contrast agent market worth of KRW 200 billion…and entry of Ilsung Pharmaceuticals

As domestically developed products have entered in the contrast agent market, worth of KRW 200 billion currently led by Bayer Healthcare and GE Healthcare, the industry has paid attention in the dynamics of the market.

While Pamiray (Iopamidol) launched by Dongkook Pharmaceutical has established its stable position in the market with sales worth of KRW 30 billion, Daewoon Pharmaceutical is tar...